<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Warfarin therapy management.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Medical Services Commission. Warfarin therapy management. Victoria (BC): British Columbia Medical Services Commission; 2010 Oct 1. 10 p.  [30 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Atrial fibrillation  (427.31); Other venous embolism and thrombosis of unspecified site  (453.9)"/><FieldValue Value="MSH: Acenocoumarol ; Atrial Fibrillation ; International Normalized Ratio ; Medication Therapy Management ; Patient Education as Topic ; Thromboembolism ; Thrombosis ; Vitamin K ; Warfarin "/><FieldValue Value="MTH: Atrial Fibrillation ; International Normalized Ratio ; Patient education (procedure) ; Thromboembolism ; Thrombosis ; Vitamin K ; Warfarin "/><FieldValue Value="PDQ: thromboembolism ; warfarin "/><FieldValue Value="SNOMEDCT_US: Acenocoumarol  (387457003); Acenocoumarol  (79356008); Atrial fibrillation  (49436004); International normalized ratio  (165581004); International normalized ratio  (1951000175101); Maintenance therapy  (314122007); Patient education  (311401005); Thromboembolic disorder  (13713005); Thromboembolic disorder  (371039008); Thrombosis  (118927008); Thrombosis  (264579008); Thrombosis  (439127006); Vitamin K  (65183007); Vitamin K  (74226000); Warfarin  (372756006); Warfarin  (48603004)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Diseases and conditions requiring warfarin therapy, including but not limited to atrial fibrillation&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Family Practice" /><FieldValue Value="Hematology" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Pharmacology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To provide recommendations for the long term management of warfarin therapy in adults 19 years and older in the office setting&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adult patients 19 years and older in British Columbia who require warfarin therapy&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Initiation of warfarin treatment with consideration of the contraindications &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Establishment of baseline international normalized ratio (INR) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Initiation of initial dose &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Establishment of target INR &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Monitoring of INR &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dose adjustment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Maintenance therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient education &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Vitamin K &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Nicoumalone (Sintrom&amp;reg;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Changes in international normalized ratio (INR) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Morbidity and mortality &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Evidence was obtained through a systematic review of peer-reviewed literature (up to July 2009) using the databases MEDLINE, PubMed, EBSCO, Ovid, and the Cochrane Collaboration's Database for Systematic Reviews. Clinical practice guidelines from other jurisdictions for the management of warfarin therapy, oral anticoagulation, pharmacogenetics, excessive anticoagulation, vitamin K, atrial fibrillation, and target international normalized ratio (INR) were also reviewed (up to July 2009).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Not stated" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline was developed by the Guidelines and Protocols Advisory Committee, approved by the British Columbia Medical Association, and adopted by the Medical Services Commission.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Initiation of Warfarin&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Consider Contraindications&lt;/strong&gt; - Prior to initiating warfarin treatment consider the contraindications below. All contraindications are relative to a patient's risk for thrombosis weighed against the risk for bleeding (see Table 2 in the original guideline document) while on vitamin K antagonist anticoagulation therapy. For a complete list of contraindications, refer to the product monograph.&#xD;&#xA;    &lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Contraindications to Warfarin Treatment&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;        &lt;thead&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Absolute Contraindications&lt;/th&gt;&#xD;&#xA;                &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Some Relative Contraindications&lt;/th&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;        &lt;/thead&gt;&#xD;&#xA;        &lt;tbody&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;The presence of a severe or active bleeding diathesis &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Non-adherence to medication and international normalized ratio (INR) monitoring &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Pregnancy (avoided at least during the first trimester and from about 2 to 4 weeks before delivery) &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Allergy or intolerance to warfarin (consider warfarin alternative - Nicoumalone) &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Uncontrolled hypertension (greater than 180/100 mm Hg) &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Severe liver disease &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Recent surgery and procedures involving the nervous system, spine, or eye &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;        &lt;/tbody&gt;&#xD;&#xA;    &lt;/table&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Establish Baseline INR&lt;/strong&gt; - Should be done in every case and will guide further therapy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Initial Dose&lt;/strong&gt; - Initial dose of warfarin is typically 5 mg/day in most patients. A starting dose of less than 5 mg may be considered for patients greater than 70 years of age, elevated baseline INR greater than 1.1, hypoalbuminemic patients (e.g., malnourished, liver disorders, post-operative), impaired nutrition (weight &amp;lt;45 kg), heart failure, known to take medications that increase sensitivity of warfarin (see Appendix A in the original guideline document), or previously documented increased sensitivity to warfarin.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note&lt;/strong&gt;: Whenever feasible, a single strength warfarin tablet (highly recommend 1 mg only for safety and dose flexibility) should be prescribed such that doses are multiples of one tablet strength. Patients should take their warfarin once a day at the same time in the evening, and have their INR test performed in the morning. This limits diurnal variations and provides the physician with a same day window for dosage adjustment in the event of an unanticipated INR change.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Pharmacogenetics-based therapy&lt;/strong&gt; has been suggested in the estimation of the therapeutic warfarin dose by genotyping patients for single nucleotide polymorphisms that affect warfarin metabolism or sensitivity. Although Health Canada has updated the label of warfarin to include information on pharmacogenetic testing, there is currently no evidence that genotyping will improve clinically relevant outcomes in individual patients.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;4&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;INR Target and Frequency of Monitoring&lt;/strong&gt; - The optimal maintenance dose for warfarin to enable a therapeutic INR varies from patient to patient and at different times in the same patient. There is no maximal or minimal dose to maintain a therapeutic range. Two therapeutic ranges are recommended, depending on the indication for anticoagulation.&#xD;&#xA;    &lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Target INR&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;        &lt;tbody&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;                &lt;p&gt;Target INR is 2.5 with a range of 2.0 &amp;ndash; 3.0 for most indications for warfarin therapy.&lt;/p&gt;&#xD;&#xA;                &lt;p&gt;Target INR is 3.0 with a range of 2.5 &amp;ndash; 3.5 for the following indications&lt;/p&gt;&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Mechanical heart valves in mitral position &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Non-bileaflet valve in aortic position (establish desired range with a specialist physician) &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;        &lt;/tbody&gt;&#xD;&#xA;    &lt;/table&gt;&#xD;&#xA;    &lt;p&gt;Under-anticoagulation can result in recurrent venous or arterial thrombosis, while over-anticoagulation can produce minor or major hemorrhagic complications. The narrow therapeutic index and a high risk/benefit ratio necessitate close and long-term monitoring. During the first few days of treatment, the INR rises without concomitant clinical anticoagulant effect. Moreover, during the maintenance phase, dose changes may not be reflected in INR for 4 to 5 days. For these reasons, &lt;strong&gt;frequent dose changes are not recommended&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;During the induction or initiation phase, it is recommended that INR be monitored every 2 to 4 days (initially daily if on therapeutic heparin) until the INR is in the patient's target range for two consecutive values. Once the INR is stabilized within the patient's target range, it can be monitored weekly. The interval can be gradually increased up to every 4 weeks if the INR remains stable and within the therapeutic range. A flowchart outlining the recommended INR testing interval is provided in the original guideline document.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Notes&lt;/strong&gt;: Increase frequency of INR (every 2 to 4 days) if any of the following happens: non-therapeutic INR, intercurrent illness, any medication change (including herbal), or significant diet change.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Some reasons for NOT changing the dose when the INR is not therapeutic:&lt;/p&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Patient noncompliant (forgot doses or took too many doses) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Inadequate number of days before previous dose change to take full effect &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Binge alcohol use (will transiently elevate INR) &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;5&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Dosage Adjustment &amp;amp; Maintenance Therapy&lt;/strong&gt; - Dosage adjustment is not required for minor fluctuations of INR as long as the results remain within the patient's target range. Fluctuations of INR beyond the patient's target range should always prompt a direct communication with patient to determine cause. Consider causes such as a change in dosage of warfarin, patient compliance, medications including over the counter medications (OTCs), dietary changes, unusual alcohol consumption, or intercurrent illness.&#xD;&#xA;    &lt;p&gt;The recent trend is to change the total weekly warfarin dose (TWD). For example, if the patient is taking 5 mg/day, the weekly dose is 35 mg. If the dose must be decreased by 10%, then the weekly dose should be 35 mg - 3.5 mg=31.5 mg and the daily dose becomes 31.5 mg/7=4.5 mg.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Table. Dosage Adjustments for Patients on Warfarin Maintenance Therapy (Target INR 2.0-3.0 or 2.5-3.5, No Significant Bleeding)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Dosage Adjustments for Patients on Warfarin Maintenance Therapy&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;        &lt;thead&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;INR&lt;/th&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;strong&gt;Intervention&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;                (Refer to flowchart in the original guideline document for timing of next INR)&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;        &lt;/thead&gt;&#xD;&#xA;        &lt;tbody&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&amp;le;1.5&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Give one time top-up equal to 20% of weekly dose and increase weekly dose by 10-20% &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1.5 &amp;lt; INR &amp;lt; therapeutic range&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;No change in dose &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;If two consecutive INRs are low, increase weekly dose by 10-20% &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;INR in therapeutic range&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;No change &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;INR &amp;gt; therapeutic range but &amp;lt;5.0&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Lower weekly dose (10-20%) or consider omitting one single dose &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Increase the frequency of INR monitoring and resume therapy at 10-20% lower weekly dose when INR therapeutic &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Note: If the INR is only minimally elevated (0.1-0.4 above upper limit of the therapeutic range), dose reduction may not be necessary &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;INR 5.0&amp;ndash;9.0*&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Omit 1 to 2 doses then recheck INR &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Increase the frequency of INR monitoring and resume therapy at 10-20% lower weekly dose when INR therapeutic &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;If the patient is at high risk of serious bleeding, consider administering vitamin K** 1 to 2 mg orally &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&amp;gt;9.0;&lt;br /&gt;&#xD;&#xA;                no bleeding&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Discontinue warfarin temporarily, consider administering vitamin K 2-5 mg orally then recheck INR*** &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Increase the frequency of INR monitoring and resume therapy at 20% lower weekly dose when INR therapeutic &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Give additional vitamin K if INR is not substantially reduced by 24 hrs*** &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;        &lt;/tbody&gt;&#xD;&#xA;    &lt;/table&gt;&#xD;&#xA;    &lt;p class=&quot;Note&quot;&gt;*Bleeding risk increases exponentially from INR 5.0 to 9.0 and should be monitored closely.&lt;/p&gt;&#xD;&#xA;    &lt;p class=&quot;Note&quot;&gt;**If vitamin K is not available in your local pharmacy, it can be obtained from your local emergency room (ER). Avoid intramuscular injections of vitamin K to prevent local injection site bleeding which also reduces bioavailability.&lt;/p&gt;&#xD;&#xA;    &lt;p class=&quot;Note&quot;&gt;***The effect of a single dose of vitamin K on the INR can be expected between 8-24 hours.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Notes&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;If patient's clinical status is compromised due to bleeding, admit to an acute care facility for assessment and management. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Bleeding with a high potential for complications (e.g., elderly, propensity to fall) requires clinical judgment to determine whether to manage within the office setting or to send to an acute care facility. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The patient should be followed using the Warfarin Patient Record Sheet (available in the original guideline document; see also the &quot;Availability of Companion Documents&quot; field) or a similar log sheet and encouraged to keep their own record. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;If patient is to undergo an invasive procedure or surgery, refer to the National Guideline Clearinghouse (NGC) summary of the Medical Services Commission, British Columbia guideline, &lt;a href=&quot;/content.aspx?id=24512&quot; title=&quot;Guideline #8152&quot;&gt;Warfarin therapy &amp;ndash; management during invasive procedures and surgery&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;The most common sites of serious bleeding&lt;/strong&gt; are gastrointestinal tract, genitourinary tract, and soft tissues including wounds. An underlying cause should always be sought, especially if the INR is within the therapeutic range or lower.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;6&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Patient Education&lt;/strong&gt; - Warfarin is more likely to be used safely by a patient who is aware of the potential for drug and diet interactions, understands the need for monitoring, and can recognize the signs of over- and under-anticoagulation. The effect of warfarin may be inhibited by very high dietary or supplemental vitamin K intake. It is generally recommended that patients on warfarin try to consume the adequate intake for vitamin K (90-120 &amp;mu;g), while avoiding large fluctuations in vitamin K intake that might interfere with the adjustment of their anticoagulant dose. A separate resource guide, including resources with patient information sheets, is available with these guidelines and should be discussed with the patient (see the &quot;Patient Resources&quot; field).&#xD;&#xA;    &lt;p&gt;At the initiation of warfarin therapy, it is recommended that the physician discuss the following with the patient and/or other care providers when possible:&lt;/p&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;The reason for prescribing warfarin and duration of treatment &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The need to adhere with recommended warfarin dosage &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The importance of monitoring and the patient's target INR &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The need to take their warfarin once a day, preferably at the same time in the evening, and to have their INR test performed in the morning &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Side effects, signs of bleeding, and potential need for blood products &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Set-up an agreed upon system of communication when side effects or changes occur &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;When to call the doctor or seek urgent attention at an emergency facility &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Strongly encourage to wear Medic Alert bracelets or necklaces to assist with care in an emergency &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Review of current medications (prescription &amp;amp; non-prescription), herbal supplements and diet for potential interactions &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The need for caution when initiating or stopping other medications (including aspirin [ASA]), herbs, or supplements &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The use of a daily pill box to assist with improving patient compliance with warfarin therapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The importance of consistent vitamin K content in the diet &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The need to avoid heavy or variable alcohol consumption &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Influence of intercurrent illness &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The importance of avoiding pregnancy while taking warfarin if applicable &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The importance of not changing brands of warfarin &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The need to avoid intramuscular injections (for flu shots &amp;ndash; physicians are recommended to apply firm, prolonged pressure for several minutes after a deltoid injection) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A clinical algorithm on recommended international normalized ratio (INR) testing interval is provided in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is not specifically stated for each recommendation.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Reduction in thromboembolic events with warfarin therapy for those at risk&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Under-anticoagulation can result in recurrent venous or arterial thrombosis. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Over-anticoagulation can produce minor or major hemorrhagic complications. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Absolute Contraindications&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The presence of a severe or active bleeding diathesis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Non-adherence to medication and international normalized ratio (INR) monitoring &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pregnancy (avoided at least during the first trimester and from about 2 to 4 weeks before delivery) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Allergy or intolerance to warfarin (consider warfarin alternative - Nicoumalone) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Some Relative Contraindications&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Uncontrolled hypertension (greater than 180/100 mm Hg) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Severe liver disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Recent surgery and procedures involving the nervous system, spine or eye &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The Clinical Practice Guidelines (the &quot;Guidelines&quot;) have been developed by the Guidelines and Protocols Advisory Committee on behalf of the Medical Services Commission. The Guidelines are intended to give an understanding of a clinical problem, and outline one or more preferred approaches to the investigation and management of the problem. The Guidelines are not intended as a substitute for the advice or professional judgment of a health care professional, nor are they intended to be the only approach to the management of clinical problems. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;This guideline assumes the physician has reviewed the indications for warfarin and the duration of therapy as these are not discussed in this guideline. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Chart Documentation/Checklists/Forms" /><FieldValue Value="Clinical Algorithm" /><FieldValue Value="Patient Resources" /><FieldValue Value="Quick Reference Guides/Physician Guides" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /><FieldValue Value="Safety" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Medical Services Commission. Warfarin therapy management. Victoria (BC): British Columbia Medical Services Commission; 2010 Oct 1. 10 p.  [30 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2010 Oct 1" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Medical Services Commission, British Columbia - State/Local Government Agency [Non-U.S.]" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Medical Services Commission, British Columbia&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Guidelines and Protocols Advisory Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.bcguidelines.ca/gpac/guideline_warfarin_management.html&quot; title=&quot;BCMA Web site&quot;&gt;British Columbia Ministry of Health Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Warfarin therapy management in adults. Summary of guideline. Victoria (BC): British Columbia Medical Services Commission; 2010 Oct 1. 2 p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.bcguidelines.ca/pdf/warfarin_management_summary.pdf&quot; title=&quot;BCMA Web site&quot;&gt;British Columbia Ministry of Health Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Warfarin patient record sheet. Victoria (BC): British Columbia Medical Services Commission; 2010 Oct 1. 2 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.bcguidelines.ca/pdf/warfarin_management_patient_record_sheet.pdf&quot; title=&quot;BCMA Web site&quot;&gt;British Columbia Ministry of Health Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available: &lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Warfarin. A guide for patients. Victoria (BC): British Columbia Medical Services Commission; 2010 Oct. 2 p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.bcguidelines.ca/pdf/warfarin_management_patient_guide.pdf&quot; title=&quot;BCMA Web site&quot;&gt;British Columbia Ministry of Health Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Warfarin and food. A guide for patients. Victoria (BC): British Columbia Medical Services Commission; 2010 Oct. 1 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.bcguidelines.ca/pdf/warfarin_management_food_guide.pdf&quot; title=&quot;BCMA Web site&quot;&gt;British Columbia Ministry of Health Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on April 1, 2011. The information was verified by the guideline developer on May 12, 2011.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
